Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification

Journal of Clinical Virology

Volumn 49, Issue 4, 2010, Pages 249-253

  Yan, Celine S ^a   Hanafi, Imelda ^a   Kelleher, Anthony D ^a,b   Carr, Andrew D ^a   Amin, Janaki ^b   McNally, Leon P ^a   Cunningham, Philip H ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Lower limit of quantification; Quantification of plasma HIV 1 RNA; Real time PCR; Viral load

Indexed keywords

ACCURACY; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PERFORMANCE; PRIORITY JOURNAL; REPRODUCIBILITY; VIRUS LOAD;

HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 78149491596     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2010.08.016     Document Type: Article

References (33)

1. Marschner I.C., Collier A.C., Coombs R.W., D'Aquila R.T., DeGruttola V., Fischl M.A., et al. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998, 177:40-47.
2. Murray J.S., Elashoff M.R., Iacono-Connors L.C., Cvetkovich T.A., Struble K.A. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 1999, 13:797-804.
3. Fischl M.A. Antiretroviral therapy in 1999 for antiretroviral-naïve individuals with HIV infection. AIDS 1999, 13(Suppl 1):S49-S59.
4. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
5. Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997, 337:725-733.
6. Perelson A.S., Essunger P., Cao Y., Vesanen M., Hurley A.K., Saksela M., et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387:188-191.
7. Raboud J.M., Montaner J.S., Conway B., Rae S., Reiss P., Vella S., et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 1998, 1619.
8. Damond F., Roquebert B., Bénard A., Collins G., Miceli M., Yéni P., et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS Amplicor HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007, 45:3436-3438.
9. Highbarger H.C., Alvord W.G., Jiang M.K., Shah A.S., Metcalf J.A., Lane H.C., et al. Comparison of the Quantiplex version 3.0 assay and a sensitized Amplicor monitor assay for measurement of human immunodeficiency virus type 1 RNA levels in plasma samples. J Clin Microbiol 1999, 37:3612-3614.
10. Lima V., Harrigan R., Montaner J.S. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the amplicor assay. J Acquir Immune Defic Syndr 2009, 51:3-6.
11. Segondy M., Izopet J., Pellegrin I., Montes B., Dumon B., Pasquier C., et al. Comparison of the QUANTIPLEX HIV-1 RNA 2.0 assay with the AMPLICOR HIV-1 MONITOR 1.0 assay for quantitation of levels of human immunodeficiency virus type 1 RNA in plasma of patients receiving stavudine didanosine combination therapy. J Clin Microbiol 1998, 36:3392-3395.
12. Wirden M., Tubiana R., Marguet F., Leroy I., Simon A., Bonmarchand M., et al. Impact of discrepancies between the Abbott RealTime and Cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 2009, 47:1543-1545.
13. de Mendoza C., Koppelman M., Montès B., Ferre V., Soriano V., Cuypers H., et al. Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods 2005, 127:54-59.
14. Garcia-Diaz A., Clewley G.S., Booth C.L., Labett W., McAllister N., Geretti A.M. Comparative evaluation of the performance of the Abbott real-time human immunodeficiency virus type 1 (HIV-1) assay for measurement of HIV-1 plasma viral load following automated specimen preparation. J Clin Microbiol 2006, 44:1788-1791.
15. Katsoulidou A., Petrodaskalaki M., Sypsa V., Papachristou E., Anastassopoulou C.G., Gargalianos P., et al. Evaluation of the clinical sensitivity for the quantification of human immunodeficiency virus type 1 RNA in plasma: comparison of the new COBAS TaqMan HIV-1 with three current HIV-RNA assays-LCX HIV RNA Quantitative. VERSANT HIV-1 RNA3. 0 (bDNA) and COBAS AMPLICOR HIV-1 Monitor v1. 5. J Virol Methods 2006, 131:168-174.
16. Rouet F., Ekouevi D.K., Chaix M.L., Burgard M., Inwoley A., Tony T.D., et al. Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 2005, 43:2709-2717.
17. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 2000, 25:169-193.
18. Sloma C.R., Germer J.J., Gerads T.M., Mandrekar J.N., Mitchell P.S., Yao J.D.C. Comparison of the Abbott RealTime human immunodeficiency virus type 1 assay to the Cobas AmpliPrep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol 2009, 47:889-895.
19. Wong M.L., Medrano J.F. Real-time PCR for RNA quantitation. Bio Techniques 2005, 39:75-85.
20. Beuselinck K., van Ranst M., van Eldere J. Automated extraction of viral-pathogen RNA and DNA for high-throughput quantitative real-time PCR. J Clin Microbiol 2005, 43:5541-5546.
21. Germer J.J., Lins M.M., Jensen M.E., Harmsen W.S., Ilstrup D.M., Mitchell P.S., et al. Evaluation of the MagNA pure LC instrument for extraction of Hepatitis C virus RNA for the COBAS AMPLICOR Hepatitis C virus test, version 2.0. J Clin Microbiol 2003, 41:3503-3508.
22. Gardner S.N., Kuczmarski T.A., Vitalis E.A., Slezak T.R. Limitations of TaqMan PCR for detecting divergent viral pathogens illustrated by hepatitis A, B, C, and E, viruses and human immunodeficiency virus. J Clin Microbiol 2003, 41:2417-2427.
23. Whiley D.M., Sloots T.P. Sequence variation in primer targets affects the accuracy of viral quantitative PCR. J Clin Virol 2005, 34:104-107.
24. Manavi K. The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin Trials 2008, 9:283-286.
25. Bland J.M., Altman D.G. Measuring agreement in method comparison studies. Stat Methods Med Res 1999, 8:135-160.
26. Tang N., Huang S., Salituro J., Mak W.B., Cloherty G., Johanson J., Li Y.H., Schneider G., Robinson J., Hackett J., Swanson P., Abravaya K. A RealTime HIV-1 viral load assay for automated quantitation of HIV-1 RNA in genetically diverse group M subtypes A-H, group O and group N samples. J Virol Methods 2007, 146:236-245.
27. Stevens W., Wiggill T., Horsfield P., Coetzee L., Scott L.E. Evaluation of the NucliSens EasyQ assay in HIV-1 infected individuals in South Africa. J Virol Methods 2005, 124:105-110.
28. Yao J., Liu Z., Ko L.S., Pan G., Jiang Y. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay. J Virol Methods 2005, 129:40-46.
29. Oliver A.R., Pereira S.F., Clark D.A. Comparative evaluation of the automated Roche TaqMan real-time quantitative human immunodeficiency virus type 1 RNA PCR assay and the Roche Amplicor version 1.5 conventional PCR assay. J Clin Microbiol 2007, 45:3616-3619.
30. Hodara V., Monticelli A., Pampuro S., Salomon H., Jauregui Rueda H., Libonatti O. HIV-1 viral load: comparative evaluation of three commercially available assays in Argentina. Acta Physiol Pharmacol Ther Latinoam 1998, 48:107-113.
31. Saag M.S., Holodniy M., Kuritzkes D.R., O'Brien W.A., Coombs R., Poscher M.E., et al. HIV viral load markers in clinical practice. Nat Med 1996, 2:625-629.
32. Pas S, Rossen JWA, Schoener D, Thamke D, Pettersson A, Babiel R, et al. Peformance Evaluation of the New Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 Test Version 2.0 for Quantification of Human Immunodeficiency Virus Type I RNA. 2010;48:1195-200.
33. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of 300 antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human 301 Services. December 1, 2009;1-16.